15:51 Dec 27
Concord Biotech Ltd.
Sector Pharmaceuticals & Biotechnology
Industry Biotechnology
Concord Biotech Ltd.
Industry Biotechnology
15:51 Dec 27
Quality
75/100
High Financial Strength
Valuation
12/100
Expensive Valuation
Technical
62/100
Technically Moderately Bullish
Strength
12
Weakness
1
Opportunity
1
Threats
1
20.18 %
ROE %
18.11 %
ROA %
31.35
EPS
145.93
BVPS
30.29 %
Net Profit Margin
| Mar 2022 | Mar 2023 | Mar 2024 | TTM 2024 | ||
|---|---|---|---|---|---|
| Net Sales | 712.93 | 853.17 | 1016.94 | 1085.75 | |
| Operating Expenses + | 439.66 | 509.88 | 585.39 | 627.57 | |
| Raw Material | 187.99 | 195.84 | 241.28 | 294.29 | |
| Increase Decrease in Cost | -23.98 | -15.63 | -12.08 | -33.74 | |
| Other Manufacturing Expense | 0 | 0 | 0 | 0 | |
| Employee Cost | 95.69 | 110.28 | 123.05 | 129.95 | |
| Miscellaneous Expenses | 241.42 | 276.93 | 346.62 | 237.07 | |
| Operating Profit | 273.27 | 343.29 | 431.55 | 458.18 | |
| Other Income | 23.42 | 35.31 | 33.78 | 39.34 | |
| Depreciation | 50.05 | 54.03 | 53.59 | 53.75 | |
| Interest | 5.48 | 4.51 | 2.55 | 1.3 | |
| Profit before tax and exceptio.. | 241.16 | 320.05 | 409.19 | 442.47 | |
| Exceptional Items | 0 | 0 | 0 | 0 | |
| PBT | 241.16 | 320.05 | 409.19 | 442.47 | |
| Provision for Taxation | 62.59 | 81.93 | 104.46 | 113.75 | |
| Net Profit | 178.57 | 238.13 | 304.73 | 328.7 | |
| NET Profit after MI | 174.93 | 240.09 | 308.1 | 327.92 | |
| EPS | 16.72 | 22.95 | 29.45 | 31.34 | |
| Operating Profit Margin (%) | 38.33 | 40.24 | 42.44 | 42.2 | |
| Net Profit Margin (%) | 24.54 | 28.14 | 30.3 | 30.2 |
ShareHolding
Promoter
FII
Public
Mutual Funds
Other Institutions
All Data in Percentage (%)
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|
| Promoter | 44.10 | 44.10 | 44.10 | 44.10 |
| FII | 8.10 | 7.10 | 6.50 | 7.00 |
| MF | 5.00 | 5.30 | 5.20 | 5.60 |
| Public | 38.00 | 38.40 | 41.00 | 40.50 |
| Others | 0.00 | 0.00 | 0.00 | 0.00 |
| Others | 4.80 | 5.10 | 3.20 | 2.80 |
| Shareholder | Shares | Holding % |
|---|
Download Our App On:
